[1]Óྲö© ºúÐÀ Ò¶ÏòÈÙ ³ÂÑå Áõ³¬.2021ÄêÅ·ÖÞ¼××´ÏÙѧ»á/Å·ÖÞGravesÑÛ²¡×¨¼Ò×éGravesÑÛ²¡¹ÜÀíÖ¸ÄÏ:½â¶ÁÓë˼¿¼[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2022,42(04):250-255,275.[doi:10.3760/cma.j.cn121383-20211003-10002]
¡¡Yu Jingwen,Hu Xin,Ye Xiangrong,et al.Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].International Journal of Endocrinology and Metabolism,2022,42(04):250-255,275.[doi:10.3760/cma.j.cn121383-20211003-10002]
µã»÷¸´ÖÆ

2021ÄêÅ·ÖÞ¼××´ÏÙѧ»á/Å·ÖÞGravesÑÛ²¡×¨¼Ò×éGravesÑÛ²¡¹ÜÀíÖ¸ÄÏ:½â¶ÁÓë˼¿¼()
·ÖÏíµ½£º

¡¶¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾¡·[ISSN:1673-4157/CN:12-1383/R]

¾í:
42
ÆÚÊý:
2022Äê04ÆÚ
Ò³Âë:
250-255,275
À¸Ä¿:
×ÛÊö
³ö°æÈÕÆÚ:
2022-07-20

ÎÄÕÂÐÅÏ¢/Info

Title:
Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy
×÷Õß:
Óྲö©12 ºúÐÀ1 Ò¶ÏòÈÙ2 ³ÂÑå3 Áõ³¬1
1ÄϾ©ÖÐÒ½Ò©´óѧ¸½ÊôÖÐÎ÷Ò½½áºÏÒ½ÔºÄÚ·ÖÃÚ¿Æ 210028; 2±±¾©ÖÐÒ½Ò©´óѧÏÃÃÅÒ½ÔºÄÚ·ÖÃÚ¿Æ 361000; 3½­ËÕÊ¡ÖÐÒ½Ò©Ñо¿ÔºÖÐÒ©×é·ÖÓë΢Éú̬Ñо¿ÖÐÐÄ 210028
Author(s):
Yu Jingwen12 Hu Xin1 Ye Xiangrong2 Chen Yan3 Liu Chao1.
1Department of Endocrinology, the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China; 2Department of Endocrinology, the Affiliated Hospital of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Xiamen 361000, China; 3Multi-component of Traditional Chinese Medicine and Microecology Research Center, Jiangsu Provincial Academy of Chinese Medicine, Nanjing 210028, China
¹Ø¼ü´Ê:
GravesÑÛ²¡ ÌÇƤÖʼ¤ËØ ÐÂÐÍ°ÐÏòÖÎÁÆ ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×
Keywords:
Graves' orbitopathy Glucocorticoids New targeted biological agents COVID-19
DOI:
10.3760/cma.j.cn121383-20211003-10002
ÕªÒª:
2021Äê7ÔÂ,Å·ÖÞ¼××´ÏÙѧ»á/Å·ÖÞGravesÑÛ²¡×¨¼Ò×é(EUGOGO)ÔÚ2016°æµÄ»ù´¡Éϸüз¢²¼ÁËGravesÑÛ²¡(Graves' orbitopathy,GO)¹ÜÀíÖ¸ÄÏ¡£ÐÂÖ¸ÄÏ»ùÓÚ×îÐÂѭ֤ҽѧ֤¾Ý²¢¶ÔÎÄÏ×½øÐÐϵͳ»Ø¹Ë,¶Ôз¢ÏÖµÄΣÏÕÒòËØ¡¢°éGO»¼Õߵļ××´ÏÙ¹¦ÄܹÜÀí¡¢ÖÐÖضȻÐÔÍ»ÑÛµÄÒ»ÏߺͶþÏßÖÎÁÆÑ¡Ôñ¡¢ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÒßÇéÏÂGO¹ÜÀíµÈÎÊÌâ½øÐÐÁËÏêϸ²ûÊö¡¢ÐÞ¶©»òÄÚÈÝÔö²¹¡£ÐÂÖ¸Äϸø³ö32ÌõÃ÷È·ÍƼöºÍ4¸ö¼²²¡¹ÜÀí·¾¶ÒÔÆڹ淶Õï¶Ï¡¢ÖÎÁƼ°ÓÐЧԤ·ÀGO¡£
Abstract:
In July 2021, the European Thyroid Association/European Group(EUGOGO)on Graves'Orbitopathy(GO)updated and published the Practice Guidelines on the basis of 2016 edition. The new guidelines made a systematic review of the literature and listed new risk factors, treatment of hyperthyroidism in patients with GO, the first-line and second-line therapy for moderate-to-severe and active GO and management of GO during COVID-19 pandemic in detail on the basis of latest evidence-based medicine. The editorial board proposed 32 specific recommendations and 4 algorithm for standardize diagnosis, treatment, and effective prevention of GO.

²Î¿¼ÎÄÏ×/References:

[1] Perros P,Z¡¦arkovic' M,Azzolini C,et al.PREGO(presentation of Graves' orbitopathy)study:changes in referral patterns to European Group On Graves' Orbitopathy(EUGOGO)centres over the period from 2000 to 2012[J].Br J Ophthalmol,2015,99(11):1531-1535.DOI:10.1136/bjophthalmol-2015-306733.
[2] Bartalena L,Baldeschi L,Dickinson A,et al.European Group on Graves' Orbitopathy(EUGOGO).Consensus statement of the European Group on Graves' Orbitopathy(EUGOGO)on management of GO[J].Eur J Endocrinol,2008,158(3):273-285.DOI:10.1530/EJE-07-0666.
[3] Bartalena L,Baldeschi L,Boboridis K,et al.The 2016 European Thyroid Association/Europea Group on Graves' Orbitopathy Guideline for the Management of Graves' Orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[4] Bartalena L,Kahaly GJ,Baldeschi L,et al.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[5] Jain AP,Gellada N,Ugradar S,et al.Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease[J].Br J Ophthalmol,2022,106(2):165-171.DOI:10.1136/bjophthalmol-2020-317806.
[6] Sabini E,Mazzi B,Profilo MA,et al.High serum cholesterol is a novel risk factor for Graves' orbitopathy:results of a cross-sectional study[J].Thyroid,2018,28(3):386-394.DOI:10.1089/thy.2017.0430.
[7] Naselli A,Moretti D,Regalbuto C,et al.Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves' ophthalmopathy to parenteral corticosteroids[J].Front Endocrinol(lausanne),2020,11:609895.DOI:10.3389/fendo.2020.609895.
[8] Nilsson A,Tsoumani K,Planck T.Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease[J].J Clin Endocrinol Metab,2021,106(5):1325-1332.DOI:10.1210/clinem/dgab070.
[9] Ye X,Bo X,Hu X,et al.Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy[J].Clin Endocrinol(Oxf),2017,86(2):247-255.DOI:10.1111/cen.13170.
[10] Kahaly GJ,Riedl M,König J,et al.Mycophenolate plus methylprednisolone versus methylprednisolone alone in active,moderate-to-severe Graves' orbitopathy(MINGO):a randomised,observer-masked,multicentre trial[J].Lancet Diabetes Endocrinol,2018,6(4):287-298.DOI:10.1016/S2213-8587(18)30020-2.
[11] Riedl M,Kolbe E,Kampmann E,et al.Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy[J].J Endocrinol Invest,2015,38(2):177-182.DOI:10.1007/s40618-014-0227-x.
[12] Salvi M,Vannucchi G,Currò N,et al.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy:a randomized controlled study[J].J Clin Endocrinol Metab,2015,100(2):422-431.DOI:10.1210/jc.2014-3014.
[13] Slentz DH,Nelson CC,Smith TJ.Teprotumumab:a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy[J].Expert Opin Investig Drugs,2020,29(7):645-649.DOI:10.1080/13543784.2020.1772752.
[14] Kahaly GJ,Douglas RS,Holt RJ,et al.Teprotumumab for patients with active thyroid eye disease:a pooled data analysis,subgroup analyses,and off-treatment follow-up results from two randomised,double-masked,placebo-controlled,multicentre trials[J].Lancet Diabetes Endocrinol,2021,9(6):360-372.DOI:10.1016/S2213-8587(21)00056-5.
[15] Douglas RS,Kahaly GJ,Patel A,et al.Teprotumumab for the treatment of active thyroid eye disease[J].N Engl J Med,2020,382(4):341-352.DOI:10.1056/NEJMoa1910434.
[16] Smith TJ,Kahaly GJ,Ezra DG,et al.Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[17] Pérez-Moreiras JV,Varela-Agra M,Prada-S¨¢nchez MC,et al.Steroid-resistant graves' orbitopathy treated with tocilizumab in real-world clinical practice:a 9-year single-center experience[J].J Clin Med,2021,10(4):706.DOI:10.3390/jcm10040706.
[18] S¨¢nchez-Bilbao L,Martínez-López D,Revenga M,et al.Anti-¢ò-6 receptor tocilizumab in refractory Graves' orbitopathy:national multicenter observational study of 48 patients[J].J Clin Med,2020,9(9):2816.DOI:10.3390/jcm9092816.
[19] Perez-Moreiras JV,Gomez-Reino JJ,Maneiro JR,et al.Tocilizumab in Graves orbitopathy study group.Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy:a randomized clinical trial[J].Am J Ophthalmol,2018,195:181-190.DOI:10.1016/j.ajo.2018.07.038.
[20] Hamed Azzam S,Kang S,Salvi M,et al.Tocilizumab for thyroid eye disease[J].Cochrane Database Syst Rev,2018,11(11):CD012984.DOI:10.1002/14651858.CD012984.pub2.
[21] Lee SJ,Rim TH,Jang SY,et al.Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections[J].Graefes Arch Clin Exp Ophthalmol,2013,251(1):261-270.DOI:10.1007/s00417-012-2153-y.
[22] Huebert I,Heinicke N,Kook D,et al.Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia[J].J Cataract Refract Surg,2015,41(10):2092-2101.DOI:10.1016/j.jcrs.2015.10.051.
[23] Muller I,Cannavaro D,Dazzi D,et al.SARS-CoV-2-related atypical thyroiditis[J].Lancet Diabetes Endocrinol,2020,8(9):739-741.DOI:10.1016/S2213-8587(20)30266-7.
[24] Mizuno S,Inaba H,Kobayashi KI,et al.A case of postpartum thyroiditis following SARS-CoV-2 infection[J].Endocr J,2021,68(3):371-374.DOI:10.1507/endocrj.EJ20-0553.
[25] Vera-Lastra O,Ordinola Navarro A,Cruz Domiguez MP,et al.Two cases of Graves' disease following SARS-CoV-2 vaccination:an autoimmune/inflammatory syndrome induced by adjuvants[J].Thyroid,2021,31(9):1436-1439.DOI:10.1089/thy.2021.0142.
[26] Iremli BG,ÿðþ‰Cendur SN,Ünlütürk U.Three cases of subacute thyroiditis following SARS-CoV-2 vaccine:postvaccination ASIA syndrome[J].J Clin Endocrinol Metab,2021,106(9):2600-2605.DOI:10.1210/clinem/dgab373.
[27] Bartalena L,Chiovato L,Marcocci C,et al.Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic[J].J Endocrinol Invest,2020,43(8):1149-1151.DOI:10.1007/s40618-020-01293-7.
[28] Neumann S,Krieger CC,Gershengorn MC.Targeting TSH and IGF-1 receptors to treat thyroid eye disease[J].Eur Thyroid J,2020,9(Suppl 1):59-65.DOI:10.1159/000511538.
[29] Krause G,Eckstein A,Schülein R.Modulating TSH receptor signaling for therapeutic benefit[J].Eur Thyroid J,2020,9(Suppl 1):66-77.DOI:10.1159/000511871.
[30] Masetti G,Ludgate M.Microbiome and Graves' orbitopathy[J].Eur Thyroid J,2020,9(Suppl 1):78-85.DOI:10.1159/000512255.

ÏàËÆÎÄÏ×/References:

[1]ÃÏÊ绪,κ¾üƽ.TSHRÐźÅתµ¼Í¨Â·ÔÚGravesÑÛ²¡·¢²¡»úÖÆÖеÄ×÷ÓÃ[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2014,(02):84.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
¡¡Meng Shuhua,Wei Junping..Roles of TSHR signal transduction pathway in Graves' ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2014,(04):84.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
[2]Ëïºìˬ,Ø¿´º³Ç,ÖìСÀö,µÈ.11¦Â-HSD1ÔÚÌÇƤÖʼ¤ËØÁªºÏ¸ß֬ιÑø ´óÊóÒȵºËصֿ¹ÖеÄ×÷ÓÃ[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2016,36(01):14.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
¡¡Sun Hongshuang*,Nie Chuncheng,Zhu Xiaoli,et al.Effects of 11¦Â-hydroxysteroid dehydrogenase type 1 on insulin resistance in rats induced by glucocorticoid and high fat diet[J].International Journal of Endocrinology and Metabolism,2016,36(04):14.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
[3]²ÜÁÕ Ö£Èʶ« ²Üö© Ðí¾ê Ëïºéƽ Áõ³¬.¼××´ÏÙÏà¹ØÐÔÑÛ²¡ÖÎÁÆнøÕ¹[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2019,39(01):25.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
¡¡Cao Lin,Zheng Rendong,Cao Wen,et al.Update on the management of thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2019,39(04):25.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
[4]½³¿ÑÅ,³Â¹ú·¼,ÐìÊ麼,µÈ.¼××´ÏÙÏà¹ØÐÔÑÛ²¡´¦ÀíµÄÐÂÊÓ½Ç:¾Ö²¿×¢ÉäÁÆ·¨[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2023,43(02):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
¡¡Lu Chenya,Chen Guofang,Xu Shuhang,et al.Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2023,43(04):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
[5]¹ùΰºì,ºÎÇì.21-ôÇ»¯Ã¸È±ÏÝÖ¢µÄΧÈÑÉïÆÚ¹ÜÀíÑо¿½øÕ¹[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2023,43(02):128.[doi:10.3760/cma.j.cn121383-20211202-12006]
¡¡Guo Weihong,He Qing..Peripregnancy management of 21-hydroxylase deficiency[J].International Journal of Endocrinology and Metabolism,2023,43(04):128.[doi:10.3760/cma.j.cn121383-20211202-12006]
[6]Ì·æ¼ ÐìÊ麼.IL-6ÊÜÌå¼°ÆäÊÜÌ忹ÌåÔÚGravesÑÛ²¡ÖеÄ×÷ÓÃÑо¿½øÕ¹[J].¹ú¼ÊÄÚ·ÖÃÚ´úлÔÓÖ¾,2023,43(05):380.[doi:10.3760/cma.j.cn121383-20220731-07068]
¡¡Tan Jie,Xu Shuhang..Update of interleukin-6 receptor and its antibody's role in Graves' orbitopathy[J].International Journal of Endocrinology and Metabolism,2023,43(04):380.[doi:10.3760/cma.j.cn121383-20220731-07068]

±¸×¢/Memo

±¸×¢/Memo:
ͨÐÅ×÷Õß:Áõ³¬,Email:liuchao@nfmcn.com; ³ÂÑå,Email:ychen202@hotmail.com
¸üÐÂÈÕÆÚ/Last Update: 2022-06-20